Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

VK2735

VENTURE

Viking Therapeutics · Phase 2 · Completed · Enrollment 176

NCT06068946

The paper states the 2.5 mg and 15 mg ends of the weekly range, and the placebo result. It does not state each intermediate dose in the abstract cited here, so those registry arms stay n/r.

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
VK2735 (Placebo)n/rn/rn/rn/r
VK2735 (Dose #1)n/rn/rn/rn/r
VK2735 (Dose #2)n/rn/rn/rn/r
VK2735 (Dose #3)n/rn/rn/rn/r
VK2735 (Dose #4)n/rn/rn/rn/r
VK2735 2.5 mgn/rn/rn/rn/r
VK2735 15 mgn/rn/rn/rn/r
Placebo 13 weeksn/rn/rn/rn/r

Not shown

  • VK2735 (Placebo): endpoint not reported
  • VK2735 (Dose #1): endpoint not reported
  • VK2735 (Dose #2): endpoint not reported
  • VK2735 (Dose #3): endpoint not reported
  • VK2735 (Dose #4): endpoint not reported
  • VK2735 2.5 mg: endpoint not reported
  • VK2735 15 mg: endpoint not reported
  • Placebo 13 weeks: endpoint not reported